Form 8-K Viking Therapeutics, For: Sep 18
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
Viking Therapeutic (VKTX) PT Raised to $28 at SunTrust Robinson Humphrey
September 18, 2018 3:39 PM EDTSunTrust Robinson Humphrey analyst Edward Nash raised the price target on Viking Therapeutic (NASDAQ: VKTX) to $28.00 (from $14.00) while maintaining a Buy rating.
Nash commented, "Viking announced promising results from a Phase II study of VK2809 in NAFLD/hypercholesterolemia. 12-week treatment... More
Viking Therapeutic (VKTX) PT Raised to $28 at Maxim Group, Matching 'Street High'
September 18, 2018 12:31 PM EDTMaxim Group analyst Jason McCarthy raised the price target on Viking Therapeutic (NASDAQ: VKTX) to $28.00 (from $14.00) while maintaining a Buy rating. The new price target matches a Street High.
The analyst highlights:
VKTX shares are up sharply (~+80%) after announcing positive top-line 12-week P2 data for VK2809, an oral thyroid beta receptor agonist (TR), in Non-Alcoholic Fatty... MoreViking Therapeutic (VKTX) PT Raised to 'Street High' $28 at H.C. Wainwright
September 18, 2018 11:57 AM EDTH.C. Wainwright analyst Joseph Pantginis raised the price target on Viking Therapeutic (NASDAQ: VKTX) to a 'Street High' $28.00 (from $15.00) while maintaining a Buy rating.
The analsyt commented, "This morning, the highly anticipated VK2809 top-line data in non-alcoholic fatty liver disease (NAFLD) and... More
Viking Therapeutics (VKTX) Climbs 140% After Shares Resume Trading
September 18, 2018 7:37 AM EDTViking Therapeutics (NASDAQ: VKTX) Climbs 140% After Shares Resume Trading
... More